Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: Myeloablation with reduced toxicity

Experimental Hematology

Volumn 31, Issue 5, 2003, Pages 428-434

  Shimoni, Avichai ^a   Bielorai, Bella ^a   Toren, Amos ^a   Hardan, Izhar ^a   Avigdor, Abraham ^a   Yeshurun, Moshe ^a   Ben Bassat, Isaac ^a   Nagler, Arnon ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BUSULFAN; CYCLOSPORIN; METHOTREXATE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DONOR; DRUG MEGADOSE; DRUG TOXICITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HLA MATCHING; HUMAN; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; MALE; MORTALITY; MUCOSA INFLAMMATION; MYELOID LEUKEMIA; NEPHROTOXICITY; NEUTROPENIA; PARAMETER; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; SIBLING; STATISTICAL ANALYSIS; SURVIVAL; THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

EID: 0037562931     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00047-X     Document Type: Article

References (40)

1. Thomas E.D., Storb R., Clift R.A., et al. Bone marrow transplantation. N Engl J Med. 292:1975;832-843.
2. Armitage J.O. Bone marrow transplantation. N Engl J Med. 330:1994;827-838.
3. Tutschka P.J., Copelan E.A., Klein J.P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 70:1987;1382-1388.
4. Hassan M. The role of busulfan in bone marrow transplantation. Med Oncol. 16:1999;166-176.
5. Ljungman P., Hassan M., Bekassy A.N. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 20:1997;909-913.
6. Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 16:1995;31-42.
7. Dix S.P., Wingard J.R., Mullins R.E., et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 17:1996;225-230.
8. Grochow L.B., Jones R.J., Brundrett R.B., et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 25:1989;55-61.
9. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 89:1997;3055-3060.
10. Bolinger A.M., Zangwill A.B., Slattery J.T., et al. An evaluation of engraftment, toxicity and busulfan toxicity in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant. 25:2000;925-930.
11. McCune J.S., Gooley T., Gibbs J.P., et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 30:2002;167-173.
12. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 100:2002;1201-1207.
13. Bolinger A.M., Zangwill A.B., Slattery J.T., et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant. 28:2001;1013-1018.
14. Schuler U., Schroer S., Kuhnle A., et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant. 14:1994;759-765.
15. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 6:2000;548-554.
16. Andersson B.S., Gajewski J., Donato M., et al. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant. 25:2000;S35-S38.
17. Andersson B.S., Kashyap A., Gian V., et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy 2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 8:2002;145-154.
18. Schuler U.S., Renner U.D., Kroschinsky F., et al. Intravenous busulfan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol. 114:2001;944-950.
19. Bearman S.I., Appelbaum F.R., Buckner C.D., et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 6:1988;1562-1568.
20. Shimoni A., Nagler A. Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations. Leukemia. 15:2001;1967-1975.
21. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assos. 53:1958;457-481.
22. Topolsky D., Crilley P., Styler M.J., Bulova S., Brodsky I., Marks D.I. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only conditioning regimen: low incidence of failed engraftment and severe acute GVHD. Bone Marrow Transplant. 17:1996;549-554.
23. Bertz H., Potthoff K., Mertelsmann R., Finke J. Busulfan/cyclophosphamide in volunteer donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant. 19:1997;1169-1173.
24. deMagalhaes-Silverman M., Bloom E.J., Donnenberg A., et al. Toxicity of busulfan and cyclophosphamide (BUCY2) in patients with hematologic malignancies. Bone Marrow Transplant. 17:1996;329-333.
25. International Bone Marrow Transplant Registry (2001).
26. Bearman S.I. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 85:1995;3005-3020.
27. Shulman H.M., Hinterberger W. Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant. 10:1992;197-214.
28. Styler M.J., Crilley P., Biggs J., et al. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective multicenter analysis. Bone Marrow Transplant. 18:1996;171-176.
29. Rozman C., Carreras E., Qian C., et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplantation for leukemia. Bone Marrow Transplant. 17:1996;75-80.
30. McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Inter Med. 118:1992;255-267.
31. Carreras E., Bertz H., Arcese W., et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. Blood. 92:1998;3599-3604.
32. Jones R.J., Lee K.S., Beschorner W.E., et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 44:1987;778-783.
33. Couriel D.R., Giralt S., Khouri I., et al. Graft-versus-host disease (GVHD) after non-myeloablative (NMA) vs myeloablative conditioning in fully matched sibling donor transplants: an update. Biol Blood Marrow Transplant. 8:2002;85. Abstract 84.
34. Antin J.H., Ferrara J.L.M. Cytokine dysregulation and acute graft-vs-host disease. Blood. 80:1992;2964-2968.
35. Hill G.R., Crawford J.M., Cooke K.R., Brinson Y.S., Pan L., Ferrara J.L. Total body irradiation and acute graft-vs-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood. 90:1997;3204-3213.
36. Socie G., Clift R.A., Blaise D., et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 98:2001;3569-3574.
37. Davies S.M., Ramsay N.K., Klein J.P., et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol. 18:2000;340-347.
38. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood. 91:1998;756-763.
39. Nagler A., Aker M., Or R., et al. Low intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol. 29:2001;362-370.
40. Sandmaier B.M., Maloney D.G., Gooley T., et al. Nonmyeloablative hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: clinical results of a TBI-based conditioning regimen. Blood. 98:(suppl 1):2001;742. Abstract 3093.